48 completed, 45 recruiting, 25 active not recruiting, 20 not yet recruiting. 109 Phase 2, 56 Phase 1, 29 Phase 3, 5 Not applicable, 2 Phase 4.
Follow Gastroesophageal Junction Adenocarcinoma: new trials by email Literature Review of Gastroesophageal Junction Adenocarcinoma trials Research Report on Gastroesophageal Junction Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer Sintilimab, Capecitabine, Oxaliplatin - Gastroesophageal Junction Adenocarcinoma | Not applicable | Not yet recruiting | Anhui Medical University | 50 | 2026-10-01 | 2026-10-05 |
| Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma FLOT Chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Fundación Santa Fe de Bogota | 90 | 2026-10-01 | 2026-10-05 | |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 130 | 2026-09-14 | 2026-10-16 |
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-09-04 | 2026-09-14 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR Tumor-Informed ctDNA-MRD Monitoring, Clinician-Selected Standard-of-Care Postoperative Treatment - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 150 | 2026-09-01 | 2026-09-02 | |
| Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer AI-Based Digital Pathology Assessment of Treatment Response (DeepTRG) - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Recruiting | Qun Zhao | 200 | 2026-09-01 | 2026-09-30 | |
| Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma Sacituzumab Tirumotecan + Tagitanlimab - ESCC, Gastric Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 75 | 2026-08-31 | 2026-07-14 |
| Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma Retlirafusp Alfa, Oxaliplatin, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 21 | 2026-08-30 | 2026-07-17 |
| HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Hyperthermic Intraperitoneal Chemotherapy, Serplulimab, S-1 - Locally Advanced Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 48 | 2026-07-13 | 2026-10-22 |
| Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer COPOX, Radiotherapy, SHR-1701 - Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2026-07-01 | 2026-07-08 |
| Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. Oxaliplatin, Capecitabine, Tislelizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Ming Liu | 52 | 2026-07-01 | 2026-06-18 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma Tislelizumab, SKB315 for injection, Capecitabine - Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 80 | 2026-06-30 | 2026-05-27 |
| Emotional Distress and Pathologic Response in Locally Advanced Gastric/GEJ Adenocarcinoma Not applicable- observational study - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | West China Second University Hospital | 120 | 2026-06-26 | 2026-06-23 | |
| Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer Not applicable- observational study - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | West China Second University Hospital | 120 | 2026-06-26 | 2026-06-23 | |
| Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma Alternative Postoperative Treatment Regimen, Original Treatment Regimen, Postoperative Observation - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 405 | 2026-06-01 | 2026-05-22 |
| A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma Iparomlimab and Tuvonralimab (QL1706) - Gastric Cancer (Diagnosis), Gastric Cancer (GC) | Phase 4 | Not yet recruiting | Huazhong University of Science and Technology | 55 | 2026-06-01 | 2026-03-30 |
| A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment BL-M05D1, Paclitaxel, Docetaxel - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 438 | 2026-05-15 | 2026-07-08 |
Showing 20 of 185. Sign in to see all of them.
Stomach Neoplasms (90) · Adenocarcinoma Of Esophagus (29) · Carcinoma, Non-Small-Cell Lung (23) · Esophageal Neoplasms (20) · Esophageal Squamous Cell Carcinoma (15) · Colorectal Neoplasms (14) · Squamous Cell Carcinoma of Head and Neck (13) · Carcinoma, Renal Cell (11) · Carcinoma, Transitional Cell (10) · Neoplasm Metastasis (10) · Adenocarcinoma (9) · Melanoma (9) · Pancreatic Neoplasms (9) · Breast Neoplasms (8) · Small Cell Lung Carcinoma (8)
Neoplasms by Site (116) · Neoplasms (115) · Digestive System Neoplasms (113) · Digestive System Diseases (112) · Gastrointestinal Diseases (107) · Gastrointestinal Neoplasms (107) · Stomach Diseases (89) · Neoplasms by Histologic Type (41) · Neoplasms, Glandular and Epithelial (39) · Carcinoma (37) · Head and Neck Neoplasms (34) · Esophageal Diseases (29) · Lung Diseases (26) · Respiratory Tract Diseases (26) · Respiratory Tract Neoplasms (26)
Oxaliplatin (48) · Capecitabine (36) · Paclitaxel (31) · Fluorouracil (28) · pembrolizumab (27) · Leucovorin (22) · Docetaxel (19) · Ramucirumab (19) · Cisplatin (16) · Nivolumab (13) · Trastuzumab (12) · Carboplatin (10) · S 1 (combination) (9) · Radiation (8) · Taxes (8)
Eli Lilly and Company (8) · Memorial Sloan Kettering Cancer Center (6) · M.D. Anderson Cancer Center (5) · Mayo Clinic (5) · Merck Sharp & Dohme LLC (5) · Hebei Medical University (4) · Peking University (4) · Seagen, a wholly owned subsidiary of Pfizer (4) · Akeso (3) · City of Hope Medical Center (3) · National Cancer Center Hospital East (3) · National Cancer Institute (NCI) (3) · Seagen Inc. (3) · AbbVie (2) · Amgen (2)
United States (83) · China (70) · South Korea (29) · Spain (25) · Japan (21) · United Kingdom (21) · Germany (20) · France (19) · Italy (19) · Canada (17) · Taiwan (17) · Australia (16) · Belgium (13) · Poland (11) · Hungary (9)
Kohei Shitara, MD (3) · Daniel Catenacci, MD (2) · Jaffer A Ajani (2) · Jianmin Fang, Ph.D (2) · Jun Wang (2) · Qun Zhao (2) · Yelena Janjigian, MD (2) · Afsaneh Barzi, MD (1) · Ai Ping Zhou, Doctor of medcine (1)
PMID 35623069, PMID 40341124, PMID 33792646, PMID 35101941, PMID 37037952, PMID 37788341, PMID 38308771, PMID 40117530, PMID 26438119, PMID 28159014, PMID 28760152, PMID 29543932, PMID 29880231, PMID 30088161, PMID 30718072, PMID 30911859, PMID 31373648, PMID 32556731, PMID 32933498, PMID 33167735, PMID 33494793, PMID 34363528, PMID 34468869, PMID 34491815, PMID 34540013, PMID 34606846, PMID 34626550, PMID 34715810, PMID 34795131, PMID 34858829, PMID 34878659, PMID 34893523, PMID 34912120, PMID 35038433, PMID 35048809, PMID 35247086, PMID 35690072, PMID 36569905, PMID 36870941, PMID 37068504, PMID 37270871, PMID 37399357, PMID 37619980, PMID 37689733, PMID 37699333, PMID 37860278, PMID 37871604, PMID 37963317, PMID 38204489, PMID 38261316
2023 (6), 2014 (5), U10CA180820 (3), 2018 (2), 2025 (2), 2015 (1), 2016 (1), 2017 (1), P30CA014089 (1), P30CA016672 (1), P30CA033572 (1), R44CA250824 (1), U10CA021661 (1), U10CA180830 (1), U10CA180868 (1)